Trial Profile
COSMOS - COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Dec 2022
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa (Primary) ; Antiparkinsonians; Antiparkinsonians
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms COSMOS
- Sponsors AbbVie
- 01 Dec 2022 Results of sub analysis (n=401) published in the Parkinsonism and Related Disorders.
- 28 Jun 2022 Results of post-hoc analysis identifying predictors of optimal motor response with LCIG in APD patients presented at the 8th Congress of the European Academy of Neurology
- 22 Sep 2021 Results of post-hoc analysis assessing impact of levodopa-carbidopa intestinal gel (LCIG) treatment on dyskinesia duration and severity in advanced Parkinson's disease (APD) patients, presented at the 25th International Congress of Parkinson's Disease and Movement Disorders.